Insights on stocks, by experts you follow.

Mixed sentiment: heavy debt worries dominate, but a new cloud contract and manageable financing keep some bulls hopeful. • CRWV plunged about 20% in a single day, prompting alarm among traders (@ckcapitalxx). • The company carries roughly $35 billion of debt, with quarterly interest expense of $640 million—over a quarter of its revenue—and bonds yielding around 15% (@intheassembly). • Only a small slice of that debt bears the 15% rate; the blended cost is nearer 8‑9%, and loans are secured by customer contracts, supporting the AI growth thesis (@kawzinvests). • A multi‑year cloud services agreement for CRWV was announced, adding a fresh revenue stream and bolstering the AI narrative (@jasonl_capital). • Opinions split on bankruptcy risk: some chatter suggests CRWV could fail, yet others argue NVDA’s involvement makes a collapse unlikely (@daniel_koss). • Overall, many see CRWV as a high‑risk, small‑cap play vulnerable to market weakness, while a minority view its debt structure and AI demand as a buying opportunity (@jackal_quant, @ckcapitalxx).

Bullish overall, though a few skeptics note product cuts and valuation concerns. • NVDA has repeatedly set new all‑time highs, with the price climbing above $240 and approaching a $6 trillion market cap. (@mr_derivatives, @kawzinvests, @firstadopter, @ckcapitalxx, @intheassembly) • The company reported $96.2 B quarterly revenue, up 106% year‑over‑year, and guided next quarter revenue to $108 B, signaling roughly 70% year‑over‑year growth. (@jasonl_capital, @firstadopter) • Institutions are heavily buying Nvidia GPUs, praising the CUDA moat and AI demand, with many noting the stock’s dominance in data‑center sales. (@midnight_captl, @jukan05) • A few voices warn that recent product cuts—like the DGX Spark SKU halving memory while keeping price—could hurt margins and signal over‑extension. (@firstadopter) • Buy recommendations are common, with several analysts targeting entry around $230‑$240 and urging long‑term holding. (@jasonl_capital) • A split remains on valuation: some cite Michael Burry’s caution as a warning sign, while others dismiss his concerns as irrelevant. (@intheassembly, @firstadopter)

Mixed sentiment: bullish enthusiasm meets technical and debt worries. • Several analysts label NBIS a strong buy around $165‑$180, praising its AI‑cloud execution and growth potential (@investingvisual, @daniel_koss, @ckcapitalxx). • Recent charts show the stock losing its year‑long uptrend, with the 200‑day SMA near $173 and support expected around $165‑$173, hinting at further downside risk (@han_akamatsu, @ckcapitalxx). • Some investors warn that NBIS carries “massive debt” that could become unsustainable if cash flow weakens (@biotech2k1). • The market’s extreme swings are evident: NBIS swings wildly with AI‑infrastructure sentiment, reflecting broader volatility in the sector (@daniel_koss, @ckcapitalxx). • A Microsoft pull‑back from the NScale deal is seen as a tailwind, potentially boosting NBIS as an alternative supplier (@aleabitoreddit). • Valuation appears attractive, with NBIS trading at roughly 3× 2027 EV/revenues and expected to beat Q3 earnings, driven by $30‑$50 M per MW contracts (@jonahlupton).